People with diagnosed diabetes make up approximately 8.5% of U.S. adults, yet they account for more than 37% of the 340B-related lost commercial rebates and patient upcharges examined in this study. In 2025 alone, commercially insured people with diabetes and their health plans incurred an estimated $4.8 billion in additional drug spending from displaced rebates, while commercially insured people with diabetes paid an estimated $156 million in out-of-pocket upcharges.

Drawing on national drug-purchasing and prescription-claims data, this white paper reveals how 340B-related costs can become concentrated among people already managing a chronic, high-cost condition. Download the report to explore the findings, understand how these costs arise and consider the broader implications for patients, employers and commercial health plans.